XENON PHARMACEUTICALS INC's ticker is XENE and the CUSIP is 98420N105. A total of 184 filers reported holding XENON PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 2.73 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $63,025,200 | -11.3% | 1,845,000 | 0.0% | 7.37% | -7.7% |
| Q2 2023 | $71,032,500 | +7.6% | 1,845,000 | 0.0% | 7.98% | -20.6% |
| Q1 2023 | $66,032,550 | +100837.9% | 1,845,000 | +11.2% | 10.05% | +2.0% |
| Q4 2022 | $65,419 | -99.9% | 1,659,111 | +4.0% | 9.86% | +6.5% |
| Q3 2022 | $57,577,000 | +18.7% | 1,594,932 | 0.0% | 9.26% | -9.7% |
| Q2 2022 | $48,518,000 | +32.0% | 1,594,932 | +32.6% | 10.26% | +24.9% |
| Q1 2022 | $36,764,000 | +8.0% | 1,202,613 | +10.3% | 8.21% | +4.1% |
| Q4 2021 | $34,056,000 | +284.6% | 1,090,126 | +88.1% | 7.89% | +237.9% |
| Q3 2021 | $8,854,000 | +45.7% | 579,432 | +77.6% | 2.33% | +10.3% |
| Q2 2021 | $6,076,000 | +12.6% | 326,336 | +8.3% | 2.12% | -1.5% |
| Q1 2021 | $5,395,000 | -24.9% | 301,392 | -35.5% | 2.15% | -45.0% |
| Q4 2020 | $7,188,000 | – | 467,368 | – | 3.91% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ghost Tree Capital, LLC | 850,000 | $15,215,000 | 3.58% |
| ACUTA CAPITAL PARTNERS, LLC | 412,500 | $7,384,000 | 2.66% |
| BVF INC/IL | 3,481,778 | $62,324,000 | 2.34% |
| Soleus Capital Management, L.P. | 708,117 | $12,675,000 | 2.28% |
| COMMODORE CAPITAL LP | 301,392 | $5,395,000 | 2.15% |
| DAFNA Capital Management LLC | 406,535 | $7,277,000 | 1.73% |
| Parkman Healthcare Partners LLC | 374,395 | $6,702,000 | 1.56% |
| Avoro Capital Advisors LLC | 3,650,000 | $65,335,000 | 1.13% |
| KNOTT DAVID M | 144,101 | $2,579,000 | 1.10% |
| Orbimed Advisors | 2,497,917 | $44,713,000 | 0.42% |